Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From LNS Added to Complementary Foods
- Conditions
- Iron Deficiency
- Interventions
- Dietary Supplement: Iron sulphateDietary Supplement: Iron pyrophosphate (FePP)Dietary Supplement: micronutrient powderDietary Supplement: micronutrient powder (containing FeSO4), phytase
- Registration Number
- NCT01991626
- Lead Sponsor
- Swiss Federal Institute of Technology
- Brief Summary
Previous studies on iron absorption have focused on the effects on the addition of iron absorption enhancers like ascorbic acid and EDTA to a meal and more recently the enzymatic phytic acid removal through phytase. The investigators want here to investigate the effects of fat on iron absorption with and without the addition of exogenous phytase as a potential iron absorption enhancer in lipid nutrient supplements (LNS) products compared to micronutrient powder(MNP) products.
Furthermore the investigators will evaluate the effects of Lipids- on iron absorption to induce the ileal brake by ingestion of a fat emulsion prior to a meal. Increasing the caloric density of a meal by increasing its fat content might enhance iron absorption by delaying gastric emptying, gastric acid secretion and increasing Fe stomach residence time.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 47
Reproductive age females 18-45 years
- Normal body mass index (17.5-25 kg/m2)
- No intake of mineral/vitamin supplements 2 weeks before and during the study
- No metabolic or gastrointestinal disorders
- No food allergies or other chronic disorders or eating disorders assessed by self-report
- Having received full oral and written information about the aims and procedures of the study
- Willing to comply with the study procedure
- Having provided oral and written informed consent
- Regular intake of medication (except oral contraceptives)
- Blood donation or significant blood loss (accident, surgery) over the past 4 months
- Currently participating in another clinical trial or having participated in another clinical trial during the last 30 days prior to the beginning of this study
- Former participation in a study involving administration of iron stable isotopes
- Subject who cannot be expected to comply with study protocol
- Pregnancy or lactation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description FeSO4- Emulsion before Iron sulphate Fat emulsion taken before a maize meal containing FeSO4 FePP-Emulsion mixed Iron pyrophosphate (FePP) Fat emulsion mixed to the meal containing FePP MNP-control micronutrient powder maize meal containing micronutrient powder (MNP) FeSO4 control Iron sulphate Maize meal containing FeSO4 FePP control Iron pyrophosphate (FePP) Maize meal containing FePP FeSO4-Mixed Iron sulphate meals containing FeSO4 mixed with a fat emulsion LNS-Phytase micronutrient powder (containing FeSO4), phytase Maize meal mixed with LNS containing micronutrient powder and phytase LNS micronutrient powder Maize meal mixed with Lipid Nutrient Supplement (LNS) containing micronutrient powder phytase micronutrient powder (containing FeSO4), phytase Maize meal containing micronutrient powder and phytase FePP-Emulsion before Iron pyrophosphate (FePP) Fat emulsion taken before a meal containing FePP
- Primary Outcome Measures
Name Time Method Iron bio-availability from Oral Iron Supplements 14 days Iron bioavailability will be assessed with stable isotopic labels. The shift in the isotopic ratio in human whole blood 14 days after administration will be measured with mass spectrometry.
- Secondary Outcome Measures
Name Time Method